Clinical trials referenced in this document:
Documents that mention this clinical trial
Hospitalizations in patients with idiopathic pulmonary fibrosis
Clinical Outcomes of Patients with Combined Idiopathic Pulmonary Fibrosis and Emphysema in the IPF-PRO Registry
Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry
Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry
Funding for this research was provided by:
The IPF-PRO™ Registry is funded by Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and co-ordinated by the Duke Clinical Research Institute (DCRI).
Received: 6 May 2021
Accepted: 23 September 2021
First Online: 30 September 2021
: The study was approved by the Duke University Institutional Review Board (Pro00046131). The protocol was also approved by the relevant Institutional Review Boards and/or local Independent Ethics Committees prior to patient enrolment at each site listed in the Acknowledgments. All patients provided informed consent.
: Not applicable.
: HJK is a member of the Publication Committee for the IPF-PRO/ILD-PRO Registry. LDS and MLN are faculty members in the Duke Clinical Research Institute (DCRI), which receives funding support from Boehringer Ingelheim Pharmaceuticals, Inc to co-ordinate the IPF-PRO/ILD-PRO Registry. AA reports grants and personal fees from Boehringer Ingelheim, personal fees from Genentech and grants from the Pulmonary Fibrosis Foundation and the National Institutes of Health. SB, ESW and CSC are employees of Boehringer Ingelheim Pharmaceuticals, Inc. MES reports grants, personal fees and non-financial support from Boehringer Ingelheim; grants from Galapagos; and personal fees from FibroGen.